bortezomib + pegylated liposomal doxorubicin + dexamethasone

This is a three-drug combination regimen used primarily in the treatment of multiple myeloma. Bortezomib is a small molecule proteasome inhibitor that disrupts protein degradation in cancer cells, leading to apoptosis. Pegylated liposomal doxorubicin is an anthracycline antibiotic encapsulated in a liposome with polyethylene glycol, which enhances drug delivery and reduces toxicity; it intercalates DNA and inhibits topoisomerase II, causing DNA damage and cell death. Dexamethasone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties that also induces apoptosis in certain hematologic malignancies. The combination has demonstrated efficacy as both frontline and relapsed/refractory therapy for multiple myeloma, improving response rates while managing toxicity profiles[1][2][5].

Other names

PAD inductionPAD regimen